TEVA-LIOTHYRONINE TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
20-11-2019
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
LIOTHYRONINE (LIOTHYRONINE SODIUM)
Tilgjengelig fra:
TEVA CANADA LIMITED
ATC-kode:
H03AA02
INN (International Name):
LIOTHYRONINE SODIUM
Dosering :
25MCG
Legemiddelform:
TABLET
Sammensetning:
LIOTHYRONINE (LIOTHYRONINE SODIUM) 25MCG
Administreringsrute:
ORAL
Enheter i pakken:
15G/50G
Resept typen:
Prescription
Terapeutisk område:
THYROID AGENTS
Produkt oppsummering:
Active ingredient group (AIG) number: 0102421002; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2019-11-21
Preparatomtale
_ _
_Teva-Liothyronine Tablets _
_Page 1 of 17_
PRODUCT MONOGRAPH
Pr
TEVA-LIOTHYRONINE
Liothyronine Sodium Tablets
5 mcg and 25 mcg liothyronine as liothyronine sodium
USP
Hypothyroidism Therapy
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Approval:
November 20, 2019
Submission Control No: 217318
_ _
_Teva-Liothyronine Tablets _
_Page 2 of 17_
TABLE OF CONTENTS
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DRUG/LABORATORY TEST INTERACTIONS
.............................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION
............................................................................................................................12
CLINICAL PHARMACOLOGY
......................................................................................12
SUPPLY
.............................................................................................................................15
COMPOSITION
................................................................................................................15
PART III: CONSUMER INFORMATION
......................................................................16
_ _
_Teva-Liothyronine Tablets _
_Page 3 of 17_
Pr
TEVA-LIOTHYRONINE
liothyronine sodium
INDICATIONS AND CLINICAL USE
TEVA-LIOTHYRONINE is
Les hele dokumentet
